C4 Therapeutics, Inc
1 day chart
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. It leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.
Buy US stocks in Australia starting with CCCC. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CCCC
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.